Screener / SEC EDGAR /CIK 0000856982 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Merit Medical Systems Inc MMSI

Compare with peers Embed
FY2025 at a glance

Sales up 11.8%, free cash flow up to $215.7M

XBRL, from each 10-K
RevenueStatements
$1.5B from $1.4B in FY2024
FY2016FY2025
Net incomeStatements
$128.5M from $120.4M in FY2024
FY2016FY2025
Free cash flowStatements
$215.7M from $185.7M in FY2024
FY2016FY2025
EPS (diluted)Statements
$2.13 from $2.03 in FY2024
FY2016FY2025
Operating marginStatements
12.2% from 11.5% in FY2024
FY2016FY2025
Total debtStatements
$734.0M from $729.6M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (44)
EPS (ttm)
2.67
Sales (ttm)
1.6B
Net income (ttm)
160.1M
Sales growth
+11.8%
EPS growth
+4.9%
Sales Q/Q
+8.4%
Free cash flow
203.6M
Gross margin
49.4%
Oper. margin
13.5%
Net margin
9.9%
FCF margin
12.6%
ROE
9.2%
ROA
5.5%
R&D / sales
6.4%
Dividend
-
Debt/Eq
0.42
Curr. ratio
4.52
Cash
503.6M
Op. cash flow (ttm)
273.7M
EBITDA
307.9M
EBITDA margin
20.3%
Net debt
233.9M
Quick ratio
3.26
Interest cover
6.98
ROIC
5.6%
FCF after stock pay
172.2M
Debt / FCF (years)
3.42
Goodwill / assets
18.9%
Oper. margin low 5y
5.7%
Tax rate
24.8%
Stock pay / sales
2.9%
Shares out.
59.9M
Shares Y/Y
+1.8%
Book / share
29.12
Cash / share
8.40
Sales / share
26.89
Asset turnover
0.55
Inventory turns
2.33
Days sales out.
49
Sales 3Y CAGR
+9.6%
Sales 5Y CAGR
+9.5%
EPS 3Y CAGR
+18.2%
Employees
7,500
Sales / employee
215K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.5B +10.8% a year Net income 128.5M +22.9% a year
FY2016 revenue 603.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-19-000016 FY2016 net income 20.1M · NetIncomeLoss, 0000856982-19-000016 603.8M FY2016 FY2017 revenue 727.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-20-000011 FY2017 net income 27.5M · NetIncomeLoss, 0000856982-20-000011 727.9M FY2017 FY2018 revenue 882.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-21-000003 FY2018 net income 42.0M · NetIncomeLoss, 0000856982-21-000003 882.8M FY2018 FY2019 revenue 994.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-22-000013 FY2019 net income 5.5M · NetIncomeLoss, 0000856982-22-000013 994.9M FY2019 FY2020 revenue 963.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-23-000011 FY2020 net income -9.8M · NetIncomeLoss, 0000856982-23-000011 963.9M FY2020 FY2021 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-24-000015 FY2021 net income 48.5M · NetIncomeLoss, 0000856982-24-000015 1.1B FY2021 FY2022 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-25-000011 FY2022 net income 74.5M · NetIncomeLoss, 0000856982-25-000011 1.2B FY2022 FY2023 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-26-000008 FY2023 net income 94.4M · NetIncomeLoss, 0000856982-26-000008 1.3B FY2023 FY2024 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-26-000008 FY2024 net income 120.4M · NetIncomeLoss, 0000856982-26-000008 1.4B FY2024 FY2025 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000856982-26-000008 FY2025 net income 128.5M · NetIncomeLoss, 0000856982-26-000008 1.5B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +14.9% a year FY2015 $0.53 to FY2025 $2.13, 10 years
Book value per share +9.6% a year FY2015 $10.47 to FY2025 $26.20, 10 years
Free cash flow per share +24.0% a year FY2015 $0.42 to FY2025 $3.57, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $2.13$26.20$3.57
Dec 31, 2024 $2.03$23.24$3.13
Dec 31, 2023 $1.62$20.60$1.90
Dec 31, 2022 $1.29$19.84$1.20
Dec 31, 2021 $0.84$18.13$2.08
Dec 31, 2020 -$0.18$17.29$2.15
Dec 31, 2019 $0.10$16.89-$0.01
Dec 31, 2018 $0.78$17.30$0.43
Dec 31, 2017 $0.55$13.50$0.48
Dec 31, 2016 $0.45$11.10$0.46
Dec 31, 2015 $0.53$10.47$0.42

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.0B
  • − All liabilities $1.1B
  • = Net current asset value -$61.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.6B
  • − Goodwill $506.8M
  • = Tangible book value $1.1B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

MMSI against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+11.8%70th of 155 · median +10.5%
Net margin
-4.1%15.3%
9.9%63rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
9.2%73rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
12.6%63rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.4229th of 108 · median 0.69
MMSI and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $1.1B of sales to $48.5M of profit FY2021

  • Cardiovascular $1.0B
  • Endoscopy $31.5M
Revenue to Gross profit: $485.3MRevenue to Cost of revenue: $589.4MGross profit to Operating profit: $60.9MGross profit to Operating expenses: $424.4MOperating profit to Net profit: $48.5MOperating profit to Tax & other: $12.5MOperating expenses to R&D: $71.2MOperating expenses to Sales, admin & other: $353.2M Revenue: $1.1B REVENUE $1.1B +12% Y/Y Gross profit: $485.3M · 45% margin GROSS PROFIT $485.3M 45% margin · +21% Y/Y Cost of revenue: $589.4M · 55% of revenue COST OF REVENUE $589.4M 55% of revenue Operating profit: $60.9M · 6% margin OPERATING PROFIT $60.9M 6% margin Operating expenses: $424.4M · 39% of revenue OPERATING EXPENSES $424.4M 39% of revenue Net profit: $48.5M · 5% margin NET PROFIT $48.5M 5% margin Tax & other: $12.5M · 1% of revenue TAX & OTHER $12.5M 1% of revenue R&D: $71.2M · 7% of revenue R&D $71.2M 7% of revenue Sales, admin & other: $353.2M · 33% of revenue SALES, ADMIN & OTHER $353.2M 33% of revenue

From $1.2B of sales to $74.5M of profit FY2022

  • Cardiovascular $1.1B
  • Endoscopy $32.8M
Revenue to Gross profit: $519.1MRevenue to Cost of revenue: $631.9MGross profit to Operating profit: $87.6MGross profit to Operating expenses: $431.5MOperating profit to Net profit: $74.5MOperating profit to Tax & other: $13.0MOperating expenses to R&D: $75.5MOperating expenses to Sales, admin & other: $356.0M Revenue: $1.2B REVENUE $1.2B +7% Y/Y Gross profit: $519.1M · 45% margin GROSS PROFIT $519.1M 45% margin · +7% Y/Y Cost of revenue: $631.9M · 55% of revenue COST OF REVENUE $631.9M 55% of revenue Operating profit: $87.6M · 8% margin OPERATING PROFIT $87.6M 8% margin · +44% Y/Y Operating expenses: $431.5M · 37% of revenue OPERATING EXPENSES $431.5M 37% of revenue Net profit: $74.5M · 6% margin NET PROFIT $74.5M 6% margin · +54% Y/Y Tax & other: $13.0M · 1% of revenue TAX & OTHER $13.0M 1% of revenue R&D: $75.5M · 7% of revenue R&D $75.5M 7% of revenue Sales, admin & other: $356.0M · 31% of revenue SALES, ADMIN & OTHER $356.0M 31% of revenue

From $1.3B of sales to $94.4M of profit FY2023

  • Cardiovascular $1.2B
  • Endoscopy $36.8M
Revenue to Gross profit: $583.9MRevenue to Cost of revenue: $673.5MGross profit to Operating profit: $123.9MGross profit to Operating expenses: $459.9MOperating profit to Net profit: $94.4MOperating profit to Tax & other: $29.5MOperating expenses to R&D: $82.7MOperating expenses to SG&A: $377.2M Revenue: $1.3B REVENUE $1.3B +9% Y/Y Gross profit: $583.9M · 46% margin GROSS PROFIT $583.9M 46% margin · +12% Y/Y Cost of revenue: $673.5M · 54% of revenue COST OF REVENUE $673.5M 54% of revenue Operating profit: $123.9M · 10% margin OPERATING PROFIT $123.9M 10% margin · +42% Y/Y Operating expenses: $459.9M · 37% of revenue OPERATING EXPENSES $459.9M 37% of revenue Net profit: $94.4M · 8% margin NET PROFIT $94.4M 8% margin · +27% Y/Y Tax & other: $29.5M · 2% of revenue TAX & OTHER $29.5M 2% of revenue R&D: $82.7M · 7% of revenue R&D $82.7M 7% of revenue SG&A: $377.2M · 30% of revenue SG&A $377.2M 30% of revenue

From $1.4B of sales to $120.4M of profit FY2024

  • Cardiovascular $1.3B
  • Endoscopy $54.8M
Revenue to Gross profit: $643.3MRevenue to Cost of revenue: $713.2MGross profit to Operating profit: $155.7MGross profit to Operating expenses: $487.6MOperating profit to Net profit: $120.4MOperating profit to Tax & other: $35.3MOperating expenses to R&D: $87.5MOperating expenses to SG&A: $400.2M Revenue: $1.4B REVENUE $1.4B +8% Y/Y Gross profit: $643.3M · 47% margin GROSS PROFIT $643.3M 47% margin · +10% Y/Y Cost of revenue: $713.2M · 53% of revenue COST OF REVENUE $713.2M 53% of revenue Operating profit: $155.7M · 11% margin OPERATING PROFIT $155.7M 11% margin · +26% Y/Y Operating expenses: $487.6M · 36% of revenue OPERATING EXPENSES $487.6M 36% of revenue Net profit: $120.4M · 9% margin NET PROFIT $120.4M 9% margin · +27% Y/Y Tax & other: $35.3M · 3% of revenue TAX & OTHER $35.3M 3% of revenue R&D: $87.5M · 6% of revenue R&D $87.5M 6% of revenue SG&A: $400.2M · 30% of revenue SG&A $400.2M 30% of revenue

From $1.5B of sales to $128.5M of profit FY2025

  • Cardiovascular $1.4B
  • Endoscopy $72.9M
Revenue to Gross profit: $738.3MRevenue to Cost of revenue: $777.6MGross profit to Operating profit: $184.7MGross profit to Operating expenses: $553.5MOperating profit to Net profit: $128.5MOperating profit to Tax & other: $56.2MOperating expenses to R&D: $97.4MOperating expenses to SG&A: $456.2M Revenue: $1.5B REVENUE $1.5B +12% Y/Y Gross profit: $738.3M · 49% margin GROSS PROFIT $738.3M 49% margin · +15% Y/Y Cost of revenue: $777.6M · 51% of revenue COST OF REVENUE $777.6M 51% of revenue Operating profit: $184.7M · 12% margin OPERATING PROFIT $184.7M 12% margin · +19% Y/Y Operating expenses: $553.5M · 37% of revenue OPERATING EXPENSES $553.5M 37% of revenue Net profit: $128.5M · 8% margin NET PROFIT $128.5M 8% margin · +7% Y/Y Tax & other: $56.2M · 4% of revenue TAX & OTHER $56.2M 4% of revenue R&D: $97.4M · 6% of revenue R&D $97.4M 6% of revenue SG&A: $456.2M · 30% of revenue SG&A $456.2M 30% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 8.1% FY2020: -1.0% net income ÷ equity
Net margin 8.5% FY2020: -1.0% profit per $ of sales: 128.5M ÷ 1.5B
Asset turnover 0.56× FY2020: 0.58× sales per $ of assets: 1.5B ÷ 2.7B
Leverage 1.70× FY2020: 1.74× assets per $ of equity: 2.7B ÷ 1.6B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    9.9% vs 6.8%
  • Gross margin up over 5 years
    41.6% → 48.7%
  • Return on equity below 15%
    9.2%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: 3.3% to 8.5%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 7.0× interest expense
  • Debt smaller than equity
    Debt / equity 0.42 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 4.52
  • Net debt under 3 years of free cash flow
    $233.9M net debt, 1.1 years
Debt / equity at each year end, FY2016 to FY2025: 0.65 to 0.46

Cash and shareholders

  • Free cash flow positive in 9 of 10 years
    $215.7M last year
  • Share count up over 5 years
    +9.1%
  • Cash from operations above net income
    $297.4M vs $128.5M
Free cash flow, FY2016 to FY2025: 20.8M to 215.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

MMSI's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.5B
FY2016: 603.8MFY2017: 727.9MFY2018: 882.8MFY2019: 994.9MFY2020: 963.9MFY2021: 1.1BFY2022: 1.2BFY2023: 1.3BFY2024: 1.4BFY2025: 1.5B FY2017FY2019FY2021FY2023FY2025
Net income128.5M
FY2016: 20.1MFY2017: 27.5MFY2018: 42.0MFY2019: 5.5MFY2020: -9.8MFY2021: 48.5MFY2022: 74.5MFY2023: 94.4MFY2024: 120.4MFY2025: 128.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow215.7M
FY2016: 20.8MFY2017: 24.1MFY2018: 23.2MFY2019: -360KFY2020: 119.3MFY2021: 119.3MFY2022: 69.3MFY2023: 110.9MFY2024: 185.7MFY2025: 215.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay172.2M
FY2016: 18.3MFY2017: 20.0MFY2018: 17.1MFY2019: -9.7MFY2020: 104.9MFY2021: 103.2MFY2022: 51.2MFY2023: 89.5MFY2024: 157.2MFY2025: 172.2M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.13
FY2016: 0.45FY2017: 0.55FY2018: 0.78FY2019: 0.10FY2020: -0.18FY2021: 0.84FY2022: 1.29FY2023: 1.62FY2024: 2.03FY2025: 2.13 FY2017FY2019FY2021FY2023FY2025
Diluted shares60.5M
FY2016: 44.9MFY2017: 50.1MFY2018: 53.9MFY2019: 56.2MFY2020: 55.4MFY2021: 57.4MFY2022: 57.7MFY2023: 58.4MFY2024: 59.4MFY2025: 60.5M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Cardiovascular 1.4B95.2% +10.9%
Endoscopy 72.9M4.8% +33.0%

10-K 0000856982-26-000008, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 909.5M60.0% +13.6%
International 606.4M40.0% +9.1%

10-K 0000856982-26-000008, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Cardiovascular1.0B1.1B1.2B1.3B1.4B
Endoscopy31.5M32.8M36.8M54.8M72.9M
Sum of segments1.1B1.2B1.3B1.4B1.5B

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Cardiovascular53.4M80.9M114.4M150.2M166.1M
Endoscopy7.5M6.6M9.5M5.5M18.6M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue603.8M727.9M882.8M994.9M963.9M1.1B1.2B1.3B1.4B1.5B
Cost of revenue338.8M401.6M488.0M562.5M562.7M589.4M631.9M673.5M713.2M777.6M
Gross profit265.0M326.3M394.8M432.4M401.2M485.3M519.1M583.9M643.3M738.3M
R&D45.2M51.4M59.5M65.6M57.5M71.2M75.5M82.7M87.5M97.4M
SG&A184.4M229.1M276.0M327.3M297.7M335.7M342.5M373.7M399.7M455.2M
Operating income34.9M33.1M58.6M15.4M-1.6M60.9M87.6M123.9M155.7M184.7M
Interest expense8.8M7.7M10.4M12.4M10.0M5.3M6.3M15.5M31.2M26.5M
Pretax income25.4M35.9M49.5M2.2M-13.2M53.9M82.6M112.1M150.0M170.9M
Income tax5.3M8.4M7.5M-3.3M-3.4M5.5M8.1M17.7M29.6M42.4M
Net income20.1M27.5M42.0M5.5M-9.8M48.5M74.5M94.4M120.4M128.5M
EPS (diluted)0.450.550.780.10-0.180.841.291.622.032.13
Diluted shares44.9M50.1M53.9M56.2M55.4M57.4M57.7M58.4M59.4M60.5M
Depreciation & amortization43.8M53.6M69.5M92.1M94.1M84.1M81.8M90.0M102.7M123.2M
EBITDA78.6M86.7M128.2M107.5M92.5M145.0M169.4M213.9M258.4M307.9M
Gross margin43.9%44.8%44.7%43.5%41.6%45.2%45.1%46.4%47.4%48.7%
Operating margin5.8%4.5%6.6%1.6%-0.2%5.7%7.6%9.9%11.5%12.2%
Net margin3.3%3.8%4.8%0.5%-1.0%4.5%6.5%7.5%8.9%8.5%
Revenue growth-+20.5%+21.3%+12.7%-3.1%+11.5%+7.1%+9.2%+7.9%+11.8%
EPS growth-15.1%+22.2%+41.8%-87.2%to a loss-+53.6%+25.6%+25.3%+4.9%

Cash flow

From EDGAR

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.5M4.1M6.1M9.4M14.3M16.1M18.0M21.3M28.5M43.5M
Stock-based pay / revenue0.4%0.6%0.7%0.9%1.5%1.5%1.6%1.7%2.1%2.9%
Operating lease cost-----16.0M14.2M14.9M15.9M17.5M
Operating lease cash paid---14.6M15.1M15.0M13.7M13.8M14.5M15.6M
Right-of-use assets---80.2M78.2M65.9M65.3M63.0M65.5M87.6M
Operating lease liabilities---84.3M83.8M72.2M70.7M68.3M65.1M87.5M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MMSI/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.